ArticleBioorganic & medicinal chemistry letters2009
An efficient chemical approach to bispecific antibodies and antibodies of high valency.
Article in Bioorganic & medicinal chemistry letters, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.ACS chemical biology · 2012Pooled it
- The renaissance of chemically generated bispecific antibodies.Nature reviews. Chemistry · 2021Review
- Synthesis and initial pharmacology of dual-targeting ligands for putative complexes of integrin αVβ3 and PAR2.RSC medicinal chemistry · 2020Article
- Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin αChemistry (Weinheim an der Bergstrasse, Germany) · 2017Article
- Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.Molecular pharmaceutics · 2015Article
- N-Sulfonyl-β-lactam hapten as an effective labeling reagent for aldolase mAb.Bioorganic & medicinal chemistry letters · 2015Article
- Improving the serum stability of site-specific antibody conjugates with sulfone linkers.Bioconjugate chemistry · 2014Article
- Triazine-based tool box for developing peptidic PET imaging probes: syntheses, microfluidic radiolabeling, and structure-activity evaluation.Bioconjugate chemistry · 2014Article
- Chemically programmed antibodies.Trends in biotechnology · 2014Review
- Chemically Programmed Antibodies AS HIV-1 Attachment Inhibitors.ACS medicinal chemistry letters · 2013Article
- Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.Journal of virology · 2013Article
- Facile and stabile linkages through tyrosine: bioconjugation strategies with the tyrosine-click reaction.Bioconjugate chemistry · 2013Article
- Cyclic-RGD peptides increase the adenoviral transduction of human mesenchymal stem cells.Stem cells and development · 2013Article
- Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting α5β1 integrin.Molecular pharmaceutics · 2013Article
- Highly efficient click labeling using 2-[¹⁸F]fluoroethyl azide and synthesis of an ¹⁸FN-hydroxysuccinimide ester as conjugation agent.Nuclear medicine and biology · 2012Article
- A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase.Chembiochem : a European journal of chemical biology · 2012Article
- Chemically programmed bispecific antibodies that recruit and activate T cells.The Journal of biological chemistry · 2012Article
- Synthesis of bispecific antibodies using genetically encoded unnatural amino acids.Journal of the American Chemical Society · 2012Article
- Chemically programmed antibodies targeting multiple alpha(v) integrins and their effects on tumor-related functions in vitro.Bioconjugate chemistry · 2011Article
- The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity.ChemMedChem · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Irreversible chemical programming of monoclonal aldolase antibody (mAb) 38C2 has been accomplished with beta-lactam equipped mono- and bifunctional targeting modules, including a cyclic-RGD peptide linked to either the peptide (D-Lys(6))-LHRH or another cyclic RGD unit and a small-molecule integrin inhibitor SCS-873 conjugated to (D-Lys(6))LHRH. We also prepared monofunctional targeting modules containing either cyclic RGD or (D-Lys(6))-LHRH peptides. Binding of the chemically programmed antibodies to integrin receptors alpha(v)beta(3) and alpha(v)beta(5) and to the luteinizing hormone releasing hormone receptor were evaluated. The bifunctional and bivalent c-RGD/LHRH and SCS-783/LHRH, the monofunctional and tetravalent c-RGD/c-RGD, and the monofunctional bivalent c-RGD chemically programmed antibodies bound specifically to the isolated integrin receptor proteins as well as to integrins expressed on human melanoma M-21 cells. c-RGD/LHRH, SCS-783/LHRH, and LHRH chemically programmed antibodies bound specifically to the LHRH receptors expressed on human ovarian cancer cells. This approach provides an efficient, versatile, and economically viable route to high-valency therapeutic antibodies that target defined combinations of specific receptors. Additionally, this approach should be applicable to chemically programmed vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.